Clorox
CLX · What the business does, what can go wrong, and how options sellers approach it
What it does
Clorox makes and sells consumer and professional products, mostly for the home. Its namesake bleach and disinfecting products are the best known. The company also owns brands in trash bags (Glad), cat litter (Fresh Step), charcoal (Kingsford), salad dressing (Hidden Valley), water filtration (Brita), and natural personal care (Burt's Bees). Most of its sales come from the United States.
How it makes money
Clorox sells branded products through large retailers, such as grocery chains, mass merchants, warehouse clubs, and online channels. Profit depends on the gap between what it charges and its costs for raw materials, packaging, freight, and manufacturing. It spends heavily on advertising and promotion to keep shelf space and brand loyalty. Many of its products are bought repeatedly, which makes revenue fairly steady.
Why investors own it
Investors often see Clorox as a defensive consumer staples company. People buy cleaning products, litter, and trash bags in most economic conditions. Strong brands can support pricing power, and the company has a long record of paying dividends. Some investors hold it for income and relative stability rather than fast growth.
What can go wrong
Input costs, such as resin, chemicals, and transportation, can squeeze margins if the company cannot raise prices. Retailers' private-label products compete on price, and shoppers may trade down. Demand can swing after unusual periods, such as a health scare that lifts disinfectant sales and then fades. Operational problems, like a systems disruption or supply chain trouble, can hurt shipments. Because the business is concentrated in the U.S., it has less geographic diversification.
What to watch
- Organic sales volume versus price changes
- Gross margin trends
- Commodity and freight costs
- Retail shelf space and private-label competition
- Advertising and promotion spending
- Dividend coverage by free cash flow
- Progress on supply chain and technology upgrades
Options income angle
Options on CLX are generally liquid, especially near-the-money contracts in the nearest few expirations, though spreads can be wider in farther-dated expirations and strikes far from the current price. Implied volatility tends to be relatively modest for a consumer staples stock, but it often rises ahead of quarterly earnings and when guidance or cost pressures are in question. A caution for premium sellers: a defensive stock can still gap sharply on an earnings surprise, so a covered call can cap upside while leaving the downside, and a cash-secured put can be assigned at a price well above where the stock opens after bad news.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 2, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Clorox reported net sales of $1,905 million for the quarter ended September 30, 2026, up 33% from $1,429 million a year earlier. Diluted earnings per share were $1.39, against $0.65 in the prior period. Much of the jump came from the GOJO acquisition and from comparing against a weak prior-year quarter, when shipments dropped after the company's ERP (enterprise software) switchover. Gross margin was lower.
How the business did
- Sales: Volume rose 31%. Organic sales growth, which strips out acquisitions and currency effects, was 18%. Health and Wellness net sales were $918 million, up 62%. Household rose 17%, Lifestyle 16% and International 11%.
- Margins and costs: Gross margin fell from 41.7% to 40.4%, mainly on higher commodity costs and higher manufacturing and logistics costs, partly offset by higher volume and cost savings. Advertising was $190 million, or 10.0% of net sales, against 11.6% a year ago.
- Below the operating line: Interest expense was $52 million, against $23 million, because of borrowing to fund GOJO. The effective tax rate was 16.4%, against 23.4%, mainly due to an international legal entity reorganization. Earnings before income taxes were $207 million, against $107 million.
- Segment profit: Adjusted EBIT (earnings before interest and taxes, excluding items management calls unusual) totaled $284 million, against $160 million. Health and Wellness contributed $209 million. The quarter excluded $26 million of acquisition and integration costs.
- Cash and capital return: Net cash from operations was $143 million, against $93 million. The company repurchased no shares, against $129 million of repurchases in the prior period. Dividends declared were $2.50 per share, against $2.48.
What management is watching
- Management expects the operating environment in fiscal year 2027 to stay volatile and challenging, with consumers under pressure and tariffs still evolving. It reported no significant supply chain disruptions or cost increases to date from the conflict involving Iran, but says future risks remain.
- The company says it will keep investing in its brands, capabilities and people. It describes the GOJO acquisition as a way to reduce volatility, accelerate sales growth and structurally improve margins.
- The balance sheet carries about $1,175 million of notes and loans payable, mostly commercial paper (short-term borrowing) used for GOJO and the Venture Agreement termination payment. Current liabilities exceeded current assets by $1,023 million. No borrowings were outstanding under the $1,964 million of revolving credit agreements, and the company reported compliance with its interest coverage covenant.
- The Burt's Bees trademark, carried at $322 million, had 20% or less excess fair value over its carrying value in the last annual review. The company is monitoring it for possible impairment.
Follow CLX in Kortex
The Kortex app shows CLX's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.